MedTrace Logo

IAMA-6 Oral Dose Study in Healthy Adults

NCT06300398 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-02-20

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of IAMA-6 administered orally to healthy adults.

Conditions

  • Neurodevelopmental Disorders

Interventions

DRUG

IAMA-6

IAMA-6 liquid suspension

DRUG

Placebo

Placebo-to-match IAMA-6 liquid suspension

Sponsors & Collaborators

  • Iama Therapeutics S.r.l.

    lead INDUSTRY

Principal Investigators

  • Stefano Milleri, MD · Centro Ricerche Cliniche di Verona srl

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-08
Primary Completion
2024-10-10
Completion
2024-11-20

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06300398 on ClinicalTrials.gov